Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
about
Treatment of primary Sjögren syndrome.High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial.Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.Present and future of biologic drugs in primary Sjögren's syndrome.Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain.Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.Patient burden of Sjögren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity.Current perspective on rituximab in rheumatic diseases.Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?Sjögren syndrome
P2860
Q30249011-86AB81D4-4EA8-42DB-8FC5-F806868E29C7Q30372606-B8316C3E-3A93-442D-8625-22319579F0C1Q36070691-ED8A1C67-7ED2-4377-91C5-AB9818050D8EQ38401667-535D0B66-C83C-41A2-A17F-4A0032D4844EQ38822415-F790490A-BC36-4455-8F81-BC090645D0A4Q38889818-7B911E1E-D578-487E-B2DE-8B29482E69ADQ38906337-6F153F0E-98D7-4D33-BB0F-7B18B6192B42Q40117123-D4CB3360-4084-4EE9-9CB5-3C0D745DB968Q41687111-151F717D-E779-46DE-973B-0CF178135323Q42373160-1F58BC7E-371F-4209-9AC6-52FFAEFCA2A8Q54384919-7C8F6936-7008-4F2D-9575-6CE23146589BQ55970262-7785211B-5AE0-40CF-A168-CCF9562EB13A
P2860
Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Development of the Sjögren's S ...... assessing treatment efficacy.
@ast
Development of the Sjögren's S ...... assessing treatment efficacy.
@en
type
label
Development of the Sjögren's S ...... assessing treatment efficacy.
@ast
Development of the Sjögren's S ...... assessing treatment efficacy.
@en
prefLabel
Development of the Sjögren's S ...... assessing treatment efficacy.
@ast
Development of the Sjögren's S ...... assessing treatment efficacy.
@en
P2093
P2860
P50
P356
P1433
P1476
Development of the Sjögren's S ...... assessing treatment efficacy.
@en
P2093
Aleth Perdriger
Arjan Vissink
Charles Zarnitsky
Divi Cornec
Emmanuel Nowak
Gilles Hayem
Hendrika Bootsma
Jacques Morel
Jean Jacques Dubost
Jean Sibilia
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEV114
P50
P577
2015-05-08T00:00:00Z